Dayforce (NYSE: DAY) is preparing to release its quarterly earnings on Wednesday, 2025-10-29. Here's a brief overview of what ...

Dayforce ® recurring revenue, excluding float, of $333 million, up 14% on a GAAP and constant currency basis Total revenue of $482 million, up ...

Dayforce is a global technology company providing cloud-based human capital management solutions for large businesses looking to manage their payroll, tax, benefits, and talent intelligence. The ...

An announcement from Dayforce Inc ( (DAY) ) is now available. Dayforce, Inc. reported its financial results for the third quarter of 2025, showing a 10% increase in total revenue to $482 million. The ...

Cytokinetics has revealed the results from a phase 3 trial of its hypertrophic cardiomyopathy (HCM) drug aficamten that it hopes will allow it to compete with Bristol-Myers Squibb’s first-to-market ...

Cytokinetics should hear back from the FDA next September about its marketing application for aficamten, which is vying to become the first rival to Bristol-Myers Squibb's fast-growing Camzyos for ...